U.S. Clinical Oncology Next Generation Sequencing (NGS) Market - Expected to Reach $1.5 Billion by 2024 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "U.S. Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast By Technology, By Workflow, By End Use And Trend Analysis From 2013 To 2024" report to their offering.

U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53 billion by 2024. Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer.

Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.

Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.

Companies Mentioned:

  • Illumina Incorporated
  • Roche Sequencing
  • Agilent Technologies
  • Knome Inc.
  • Genomatix Software GmbH
  • GATC Biotech Ag
  • Oxford Nanopore Technologies Ltd.
  • Macrogen Inc.
  • Life Technologies Corp.
  • DNASTAR Inc.
  • Myriad Genetics
  • Exosome Diagnostics, Inc.
  • Biomatters Ltd.
  • Life CLC Bio
  • BGI
  • Qiagen NV
  • Perkin Elmer, Inc.
  • Pacific Bioscience, Inc.
  • Partek, Inc.
  • GnuBIO (Bio-Rad)
  • Foundation Medicine Inc.
  • Paradigm Diagnostics, Inc
  • Caris Life Science

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Market Snapshot

4 Market Variables, Trends & Scope

5 Market Categorization 1: Technology Estimates & Trend Analysis

6 Market Categorization 2: Workflow Estimates & Trend Analysis

7 Market Categorization 3: End-use Estimates & Trend Analysis

8 Market Categorization 4: Regional Estimates & Trend Analysis, by Technology, Workflow&End-use

9 Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/dvgcgz/u_s_clinical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Molecular Diagnostics , Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Molecular Diagnostics , Oncology